Literature DB >> 6378927

Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.

L Skriver, L I Larsson, V Kielberg, L S Nielsen, P B Andresen, P Kristensen, K Danø.   

Abstract

The invasively growing and metastasizing Lewis lung carcinoma consistently contained urokinase-type plasminogen activator (u-PA) enzyme activity. When investigated immunocytochemically with antibodies against u-PA, different parts of individual tumors showed a pronounced heterogeneity in staining intensity. Strong staining was found in areas with invasive growth and degradation of surrounding normal tissue, while other areas were completely devoid of staining. Immunoreactivity occurred both with a perinuclear cytoplasmic localization in tumor cells and associated with apparently extracellular material. SDS PAGE of tumor extracts, under both reducing and nonreducing conditions, followed by immunoblotting, showed only one immunocytochemically stainable band with an electrophoretic mobility corresponding to that of purified proenzyme to u-PA, while no two-chain u-PA was detected. This indicates that the major part of the activator in Lewis lung carcinoma is present as one-chain pro-u-PA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378927      PMCID: PMC2113289          DOI: 10.1083/jcb.99.2.753

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  53 in total

1.  The induction of differentiation in teratocarcinoma stem cells by retinoic acid.

Authors:  S Strickland; V Mahdavi
Journal:  Cell       Date:  1978-10       Impact factor: 41.582

2.  Human endothelial cells contain one type of plasminogen activator.

Authors:  P Kristensen; L I Larsson; L S Nielsen; J Grøndahl-Hansen; P A Andreasen; K Danø
Journal:  FEBS Lett       Date:  1984-03-12       Impact factor: 4.124

3.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

4.  Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus.

Authors:  L Skriver; L S Nielsen; R Stephens; K Danø
Journal:  Eur J Biochem       Date:  1982-05-17

5.  Secretion of plasminogen activator by normal, reactive and neoplastic human tissues cultured in vitro.

Authors:  E L Wilson; E Dowdle
Journal:  Int J Cancer       Date:  1978-10-15       Impact factor: 7.396

6.  Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.

Authors:  L S Nielsen; J G Hansen; P A Andreasen; L Skriver; K Danø; J Zeuthen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

7.  Serine enzymes released by cultured neoplastic cells.

Authors:  K Danø; E Reich
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

8.  Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse.

Authors:  L I Larsson; L Skriver; L S Nielsen; J Grøndahl-Hansen; P Kristensen; K Danø
Journal:  J Cell Biol       Date:  1984-03       Impact factor: 10.539

9.  Immunological analysis of plasminogen activators from normal and transformed hamster cells. Evidence that the plasminogen activators produced by SV40 virus-transformed hamster embryo cells and normal hamster lung cells are antigenically identical.

Authors:  J K Christman; S C Silverstein; G Acs
Journal:  J Exp Med       Date:  1975-08-01       Impact factor: 14.307

10.  A study of proteases and protease-inhibitor complexes in biological fluids.

Authors:  A Granelli-Piperno; E Reich
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  26 in total

1.  Tissue-type plasminogen activator in rat adrenal medulla.

Authors:  P Kristensen; D M Hougaard; L S Nielsen; K Danø
Journal:  Histochemistry       Date:  1986

Review 2.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

3.  Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.

Authors:  P Kristensen; C Pyke; L R Lund; P A Andreasen; K Danø
Journal:  Histochemistry       Date:  1990

Review 4.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

5.  Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.

Authors:  J H Axelrod; R Reich; R Miskin
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

6.  Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line.

Authors:  E Helseth; A Dalen; G Unsgaard; R Vik
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130

Review 7.  Invasiveness of transformed bladder epithelial cells.

Authors:  J F Kieler
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

8.  DMSO-induced changes in the procoagulant and fibrinolytic activity of B16 melanoma cells: influence on lung colony formation.

Authors:  B Casali; M G Lampugnani; M Riganti; A Niewiarowska; G Alessio; L Mussoni; N Semeraro; M B Donati
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

9.  Density-dependent induction of 92-kd type IV collagenase activity in cultures of A431 human epidermoid carcinoma cells.

Authors:  B Xie; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

10.  Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Authors:  Sai Murali Krishna Pulukuri; Norman Estes; Jitendra Patel; Jasti S Rao
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.